Felbamate, 2-phenyl-l,3-propanediol dicarbamate, is a novel anticonvulsant that is effective against both chemically and electrically induced seizures in laboratory animals. Oncogenic studies were conducted in mice and rats to establish a preclinical safety profile for this drug. There was an increased incidence of hepatic cell adenoma in male and female mice and in female rats. There was an increased incidence of interstitial cell tumors of the testes bl the male rat. O 1998 Society of Toxicology.
Felbamate, 2-phenyl-l,3-propanediol dicarbamate ( Fig. 1) , is a novel antiepileptic that is effective against both chemically and electrically induced seizures in laboratory animals (Swinyard et al., 1986) . This effect has also been demonstrated in human clinical trials (Leppik et al., 1991; Sachdeoef al., 1991; Ritter et ai, 1993) and the compound was recently approved for marketing (July 1993, Felbatol) . In addition to its antiepileptic effects, it has also shown activity in in vitro (Wallis et al, 1992) and in in vivo ) models of hypoxic brain damage. There is evidence to indicate that felbamate interacts at the strychnine-insensitive glycine recognition site on the NMDA receptor-ionophore complex which may, in part, account for both its anticonvulsant and its neuroprotectant activities (McCabe et al., 1993; Wallis and Panizzon, 1993; White et al., 1994) . Oncogenic studies were conducted in mice and rats to establish a preclinical safety profile for this drug and the results are reported herein.
METHODS

Chemicals
All batches of bulk dmg used in these studies were manufactured by Wallace Laboratories and certified by analytical testing to be 100 ± 2% pure. The compound was stable in certified rodent meal for at least 2 weeks. NY) and quarantined for approximately 2 weeks. At initiation of dosing, the male mice weighed 14.0-31.0 g; the females, 18.6-32.9 g.
Animals
Rats.
Male and female weanling (3-4 weeks old) rats [Crl:CD(SD)BR] were purchased from Charles River Canada (St. Constant, Quebec, Canada) and quarantined for at least 1 week. At initiation of dosing, the male rats weighed 101-155 g; the females, 87-123 g.
Husbandry
Mice and rats were housed individually in stainless-steel suspended wire cages. Mice were fed Prolab RMH 3200 (Agway, Inc., Syracuse, NY) until Week 51 of the study and then converted to Purina Certified Rodent Chow No. 5002 (Ralston-Purina Co., St. Louis, MO) for the remainder of the study. Rats were fed Prolab RMH 3000 (Agway, Inc.) during the entire study. Water was available at all times and the animals were housed in environmentally controlled rooms with a 12-h photoperiod.
Dosing
Mice and rats were administered compound by drug-feed admixture. Drug concentrations were adjusted on a weekly basis throughout the 2-year studies to achieve daily doses of 0, 100, 600, and 1200 mg/kg for both sexes of mice; 0, 30, 100, and 300 mg/kg for male rats; and 0, 10, 30, and 100 mg/kg for female rats. These doses were based on maximum tolerated dose (90-day) studies conducted in the mouse and raL In the mouse study, body weight of both sexes was lower than controls at 1200 mg/kg. In the rat study, body weight for males was lower than controls at 300 mg/kg and lower for females at 100 mg/kg. In no instance did die body weight change exceed 10% of the mean body weight of the respective control animals. At die time dosing began, the mice were approximately 7 weeks of age and the rats were approximately 5 weeks of age.
Observations
Mortality and morbidity checks were made twice daily during the week and once daily on weekends and holidays. Body weights were recorded weekly for all animals during the study. Food and drug consumption were calculated and recorded weekly on a group basis. Indirect ophthalmic examinations were performed on all animals prior to initiation and at termination on all survivors. All animals were palpated each week and the number, location, and time of appearance of any masses were recorded. Necropsies were conducted on all animals and representative samples of abdominal skin, adrenal glands, brain, cecum, colon, duodenum, esophagus, eyes, femur, gallbladder (mouse), heart, ileum, jejunum, kidneys, larynx, liver, lungs, mesenteric lymph nodes, nasal cavity, ovaries, pancreas, pituitary gland, prostate gland, rectum, salivary glands, sciatic nerve, seminal vesicles, spleen, sternum, stomach, submaxillary lymph nodes, testes with epididymides, thigh muscle, thoracic aorta, thoracic spinal cord, thymus (if present), thyroid/parathyroid glands, tissue masses, trachea, urinary bladder, uterus, and vagina were preserved in 10% neutral buffered formalin. All tissues were trimmed, blocked, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Microscopic examinations of all tissues was conducted by Dr. D. A. Willigan (Germantown, MD).
Statistics
All tumor data were analyzed by the life-table method of McKinney (McKinney, et al, 1968) . Selected tumor data were analyzed using an exact permutation trend test (IARC, 1986) .
RESULTS
Mouse Study
The mouse study was terminated early (Week 92) due to early mortality in the control groups. There was no evidence of an intercurrent infection or other reason to explain the early mortality in the controls. No drug-induced mortality was observed during the course of the study. Body weight gain was lower at all dose levels in both sexes (Figs. 2 and  3 ). Actual mean drug consumption for each group was within 10% of the desired dose level. Dose-related plasma levels of felbamate (Table 1) were observed in both males and females at termination of the study. The levels in the female mice were approximately 50-70% less than in the males. Reduced plasma levels of felbamate in the female compared to the male were also observed in the 2-year rat oncogenic study. There were no drug-related ocular changes during the course of the study. Histopathologic examination revealed a dose-related (primarily males) hepatic cell hypertrophy due to an increase in cytoplasmic volume that is normally associated with enzyme induction. These changes were also seen in a 1-year rat study and in the rat oncogenic study (see below) conducted at our laboratory (McGee). There was an increased incidence of hepatic cell adenoma in male and female mice compared to the untreated controls. At dose levels of 0, 100, 600, and 1200 mg/kg the percentage of incidence of hepatocellular adenoma was 7.5, 11.7, 15.0, and 16.9% in the males and 2.5, 0.0, 0.0, and 11.7% in the females, respectively (Table 2) .
Rat Study
No drug-induced mortality was observed during the course of the study. Body weight was significantly reduced • p =S 0.05.
in the males at 100 and 300 mg/kg (Figs. 4 and 5) and the females at 100 mg/kg (Fig. 5) . Food consumption was reduced in the high-dose males only. Actual mean drug consumption was within 10% of the desired dose level. Although dose-related plasma levels of felbamate were seen at termination (Table 3) , the amount present in plasma was less for females versus males at comparable dose levels. There were no drug-related ocular changes during the course of the study. Histopathologic examination revealed a doserelated (males only) hepatic cell hypertrophy, cytoplasmic vesiculation of hepatic cell parenchyma and the presence of intracytoplasmic "myelin figures." These changes which are typical of enzyme induction were also seen in a 1-year rat study conducted at our laboratory (McGee). There was an increased incidence of hepatic cell adenoma in the female rats compared to the untreated controls. At dose levels of 0, 10, 30, and 100 mg/kg the percentage of incidence of hepatocellular adenoma was 0.0, 0.0, 4.0, and 6.0%, respec- tively (Table 4) . There was also an increased incidence of interstitial cell tumors of the testes in the male rat. At dose levels of 0, 30, 100, and 300 mg/kg the percent incidence of testicular tumors was 1.0, 4.0, 2.0, and 18.0%, respectively (Table 4) .
Retrospective Analysis
Because of inconsistencies in the original data (see Discussion), it was decided that additional sections should be made to determine the validity of the initial results. In the mouse study, new blocks of liver tissue from three lobes of the liver were sectioned such that each slide was prepared from a section approximately 30 /n,m distal from the preceding section. In the rat study, the original blocks of liver and testes tissue were sectioned such that each slide was prepared from a section of tissue approximately 60 /xm distal from the preceding section. New blocks were made in the case of the mouse study because resectioning of the original blocks would have resulted in destruction of other tissues embedded in the same blocks.
In the mouse and rat study, examination of additional slides of liver tissue at three levels did not reveal any drug effect on the incidence of hepatocellular adenoma and/or carcinoma (Tables 5 and 6 ). No significant trends were found when the recut levels were analyzed separately or after being combined. These results indicate that the original statistically significant changes noted in liver adenoma were fortuitous and not related to drug administration. In the rat study, examination of additional slides of testicular tissue revealed that the incidence of tumors were still statistically significant at the high-dose group at each of the recut levels (Table 7) .
DISCUSSION
Plasma levels were lower in females compared to males for both the mouse and the rat. However, the lower plasma levels in the females still achieved a maximum tolerated dose based on body weight changes seen in the oncogenic studies. Although we have no definitive explanation for this effect, it is apparently not due to enzyme induction as hepatic enzyme induction was histologically more prominent in the male animals.
Evaluation of the incidence of liver tumors in the mouse study indicated that: (1) there was not a dose-response relationship, (2) the high-dose females were significantly different from the control group by one tumor only, and (3) the incidence of liver adenoma in the control group of this study was well below our usual laboratory range. The incidence of this lesion in control female rats in our laboratory has been as high as 17% in prior studies. During examination of the liver slides from both the mouse and the rat studies, it became evident that the liver lesions were relatively small in comparison to the size of the entire liver or lobe of the liver. Evaluation of the incidence of interstitial cell tumor of the testis in the male rat revealed that: (1) there was not a dose-response relationship and (2) the incidence in the control group was unusually low. The incidence of interstitial cell tumors of the testes in control male rats has been as high as 11.6% in prior studies conducted in this laboratory.
Although it does not appear that felbamate induces tes- ticular tumors in male rats, it does appear to facilitate their development. This effect is illustrated by the increase in size of the tumors in the high-dose group versus the control. Even the apparent facilitation of growth of the spontaneous tumors appears to have a definite threshold as there was not a dose-response relationship for this tumor type. The mechanism whereby felbamate may enhance the growth of spontaneous interstitial cell tumors is under investigation at this time.
According to the literature (Butler, 1996) , phenobarbital induces an increase in acidophilic adenomas and causes a decrease in the incidence of hepatocellular carcinomas in mice. This effect has been correlated to the fact that phenobarbital is an inducer of mixed function oxidase enzymes. In our studies with felbamate, the liver adenomas were predominately of the acidophilic type and we also observed a decrease in the incidence of hepatocellular carcinoma. However, the evaluation of the recut data would indicate that the liver tumors seen with felbamate were not in fact Information available on other anticonvulsants reveals that carbamazepine (PDR, 1998) caused a dose-related increase in hepatocellular tumors in female rats and interstitial cell adenomas in the male rat. Since we do not feel that the apparent increase in liver tumors with felbamate is in fact drug related, these results are similar only in respect to the testicular tumors. Unfortunately, no information could be found on the effect of carbamazepine on hormone levels in the rat and no data is available on felbamate at this time.
